查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153488

表觀遺傳學相關藥物和診斷技術全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Epigenetics Drugs And Diagnostic Technologies Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球表觀遺傳學相關藥物和診斷技術的市場規模預計將從2025年的211.9億美元成長至2034年的1,265億美元，2026年至2034年的複合年成長率（CAGR）為21.96%。隨著研究人員不斷深入研究在不改變DNA序列的情況下影響基因活性的表觀遺傳機制，市場正在迅速擴張。表觀遺傳學在細胞功能、發育和病理狀態（包括某些癌症和其他疾病）中發揮著至關重要的作用。表觀遺傳藥物旨在修飾參與基因調控的特定生物學過程，而診斷技術則有助於識別可能提供有關疾病特徵資訊的表觀遺傳學變化。隨著人們對精準醫療和分子診斷的興趣日益濃厚，製藥公司和研究機構正在推動基於表觀遺傳機制的療法和檢測方法的開發。

市場成長的驅動力來自分子生物學的進步、藥物研發投入的增加以及先進診斷技術的日益普及。研究人員正在研究影響DNA甲基化和組蛋白修飾的化合物，尤其是在腫瘤學和其他特定治療領域。診斷技術開發人員正在尋找表觀遺傳生物標記物，用於疾病分類、預後預測和治療反應評估。定序、甲基化分析和實驗室自動化技術的進步使研究人員能夠更深入地研究表觀遺傳模式。製藥公司、生物技術公司和學術機構之間的合作也促進了新治療標靶的發現和診斷方法的開發。

該市場的未來前景取決於臨床研究的結果、生物標記的檢驗以及更安全有效的表觀遺傳療法的開發。多組體學分析和人工智慧的進步可能有助於研究人員解讀複雜的表觀遺傳數據並識別具有臨床意義的模式。改進的診斷平台將有助於更準確地對疾病進行分類，並為特定療法篩選患者。然而，與生物複雜性、脫靶效應、臨床檢驗和法規核准相關的挑戰依然十分嚴峻。為了拓展這些技術的實際應用，持續研究疾病機制以及提供更有力的證據將表觀遺傳學見解與臨床結果聯繫起來至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球表觀遺傳學相關藥物和診斷技術市場：按技術分類

  • 市場分析、洞察與預測
  • DNA甲基化
  • 組蛋白乙醯化
  • 大型非編碼RNA
  • 微型RNA修飾
  • 染色質結構

第5章 全球表觀遺傳學相關藥物和診斷技術市場：按應用領域分類

  • 市場分析、洞察與預測
  • 腫瘤學（固態腫瘤、體液腫瘤）
  • 非腫瘤應用（發炎性疾病、代謝性疾病、感染疾病、心血管疾病及其他用途）

第6章：全球表觀遺傳學相關藥物和診斷技術市場：按最終用戶分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 診斷中心
  • 其他最終用戶

第7章 全球表觀遺傳學相關藥物和診斷技術市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Eisai
    • Otsuka Pharmaceutical
    • Bristol Myers Squibb
    • AbbVie
    • AstraZeneca
    • GSK
    • Roche
    • Thermo Fisher Scientific
    • Illumina
    • QIAGEN
    • Merck KGaA
    • Novartis
    • Pfizer
    • Agilent Technologies
    • Zymo Research
    • Diagenode
    • Active Motif
    • EpigenDx
    • Chroma Medicine
    • EpiCypher
簡介目錄
Product Code: VMR11210484

The global epigenetics drugs and diagnostic technologies market size is expected to reach USD 126.50 Billion in 2034 from USD 21.19 Billion in 2025, growing at a CAGR of 21.96% during 2026-2034.This market is advancing as researchers increasingly investigate epigenetic mechanisms that influence gene activity without changing the underlying DNA sequence. Epigenetics plays an important role in cellular function, development, and disease, including certain cancers and other medical conditions. Epigenetics drugs are designed to modify specific biological processes involved in gene regulation, while diagnostic technologies help identify epigenetic changes that may provide information about disease characteristics. Growing interest in precision medicine and molecular diagnostics is encouraging pharmaceutical companies and research institutions to develop therapies and testing methods based on epigenetic mechanisms.

Market growth is driven by advances in molecular biology, increasing investment in drug discovery, and the expanding use of advanced diagnostic technologies. Researchers are investigating compounds that influence DNA methylation and histone modification, particularly in oncology and selected other therapeutic areas. Diagnostic developers are exploring epigenetic biomarkers for disease classification, prognosis, and treatment response assessment. Improvements in sequencing, methylation analysis, and laboratory automation are helping researchers investigate epigenetic patterns with greater detail. Collaborations among pharmaceutical companies, biotechnology firms, and academic institutions are also supporting the identification of new therapeutic targets and the development of diagnostic methods.

The future prospects of this market will depend on clinical research outcomes, biomarker validation, and the development of safer and more effective epigenetic therapies. Advances in multi-omics analysis and artificial intelligence may help researchers interpret complex epigenetic data and identify clinically meaningful patterns. Improved diagnostic platforms could support more precise disease classification and patient selection for specific treatments. However, challenges involving biological complexity, off-target effects, clinical validation, and regulatory approval remain significant. Continued research into disease mechanisms and stronger evidence linking epigenetic findings to clinical outcomes will be important for expanding the practical applications of these technologies.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Technology

  • DNA Methylation
  • Histone Acetylation
  • Large Non-Coding RNA
  • MicroRNA Modification
  • Chromatin Structures

By Application

  • Oncology (Solid Tumors, Liquid Tumors)
  • Non-Oncology (Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Other Applications)

By End-User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Other End Users

COMPANIES PROFILED

  • Eisai, Otsuka Pharmaceutical, Bristol Myers Squibb, AbbVie, AstraZeneca, GSK, Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Merck KGaA, Novartis, Pfizer, Agilent Technologies, Zymo Research, Diagenode, Active Motif, EpigenDx, Chroma Medicine, EpiCypher

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Technology
  • 4.2. DNA Methylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Histone Acetylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Large Non-Coding RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. MicroRNA Modification Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Chromatin Structures Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Oncology (Solid Tumors, Liquid Tumors) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Non-Oncology (Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Other Applications) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Technology
    • 7.2.2 By Application
    • 7.2.3 By End-user
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Technology
    • 7.3.2 By Application
    • 7.3.3 By End-user
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Technology
    • 7.4.2 By Application
    • 7.4.3 By End-user
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Technology
    • 7.5.2 By Application
    • 7.5.3 By End-user
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Technology
    • 7.6.2 By Application
    • 7.6.3 By End-user
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Eisai
    • 9.2.2 Otsuka Pharmaceutical
    • 9.2.3 Bristol Myers Squibb
    • 9.2.4 AbbVie
    • 9.2.5 AstraZeneca
    • 9.2.6 GSK
    • 9.2.7 Roche
    • 9.2.8 Thermo Fisher Scientific
    • 9.2.9 Illumina
    • 9.2.10 QIAGEN
    • 9.2.11 Merck KGaA
    • 9.2.12 Novartis
    • 9.2.13 Pfizer
    • 9.2.14 Agilent Technologies
    • 9.2.15 Zymo Research
    • 9.2.16 Diagenode
    • 9.2.17 Active Motif
    • 9.2.18 EpigenDx
    • 9.2.19 Chroma Medicine
    • 9.2.20 EpiCypher